Ask AI
ProCE Banner Events

Share

2025 Cardiology Intensive for Advanced Practice Providers

This dynamic half-day program is designed for nurse practitioners and physician associates, featuring expert-led presentations that delve into the latest advancements and best practices in cardiology. Participants will enhance their clinical knowledge and skills, empowering them to provide optimal care for patients with cardiovascular conditions and earn CE/CME credit.

Physician Assistants: 6.00 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 6.00 Nursing contact hours, includes 6.00 hour of pharmacotherapy credits

This event has expired. No longer available for credits.

Who Should Attend

This activity is intended for cardiology-focused nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses.

Time and location

Saturday, December 06, 2025

10:00 AM - 5:25 PM Eastern Time (ET)

Virtual

Agenda

10:00 AM - 10:05 AM ET Welcome and Introduction
Moderator: John M. Giacona, PhD, PA-C

10:05 AM - 12:05 PM ET Leading With Impact: NPs and PAs at the Center of PAH Care Transformation
Presented by Brian P. Rose, PA-C, MPH, AACC and Lauren S. Eyadiel, PA-C, CCC-SLP, FHFSA, HF-Cert

  • Gain practical, evidence-based strategies to enhance care for patients with pulmonary arterial hypertension. This interactive program equips NPs and PAs to recognize PAH earlier, apply the latest therapeutic advances, and lead collaborative, patient-centered management to improve outcomes.

Supported by an independent medical educational grant from Merck & Co., Inc., Rahway, NJ, USA.

12:05 PM - 12:10 PM ET Break

12:10 PM - 1:10 PM ET The Evidence on Obesity & CV Risk: Clinical Trials Meet Real-World
Presented by Lawrence Herman, DMSc, MPA, PA-C

  • Understand that there is a need for obesity management that addresses the relationship between cardiovascular (CV) risk and obesity in appropriate adult patients with established CV disease. Analyze the efficacy and safety data from multiple randomized, controlled trials and explore complementary real-world evidence from routine clinical practice.

This non-CME educational program is sponsored by Novo Nordisk and managed by Decera Clinical Insights, formerly Clinical Care Solutions, a CEA Company.

1:10 PM - 1:15 PM ET Break

1:15 PM - 3:15 PM ET ASCVD Prevention Through Individualized Pharmacologic and Supportive Care Management of Hyperlipidemia
Presented by Laura Ross, PA-C, MPAS, CLS, DipACLM, AACC and Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

  • Discover practical, evidence-based strategies to optimize lipid management and reduce ASCVD risk. This interactive education equips NPs and PAs to individualize therapy, integrate nonstatin and combination treatments, and lead patient-centered care to improve cardiovascular outcomes.

Supported by an independent medical education grant from Novartis Pharmaceuticals Corporation.

3:15 PM - 3:20 PM ET Break

3:20 PM – 5:20 PM ET First to See, First to Act: Empowering NPs and PAs With Frontline Strategies to Recognize and Treat ATTR-CM
Presented by: Jill Stratford Waldron, MSN, GNP, MS

  • Strengthen your skills in recognizing and managing transthyretin cardiac amyloidosis (ATTR-CM). Through expert-led discussions and practical case-based exercises, participants will learn to identify early clinical clues and apply emerging therapies to optimize patient outcomes.

This activity is supported by an educational grant from Alnylam Pharmaceuticals.

5:20 PM - 5:25 PM ET Closing Remarks
Moderator: John M. Giacona, PhD, PA-C

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners who care for patients with cardiology conditions.

Target Audience
This activity is intended for cardiology-focused nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses.

Learning Objectives
Upon completion of this activity, participants should be able to:

Leading With Impact: NPs and PAs at the Center of PAH Care Transformation

  • Differentiate key pathophysiologic pathways involved in PAH, including right heart structure and function, and their implications for diagnostic strategies
  • Evaluate the latest clinical safety and efficacy data for new and emerging PAH therapies to personalize treatment plans
  • Assess patient response to treatment and determine when to escalate therapy, including the integration of combination therapy, to optimize treatment goals
  • Leverage the unique role of an APP to bring quality of life, mental health, and shared decision-making into clinical practice to optimize patient treatment adherence and efficacy

ASCVD Prevention Through Individualized Pharmacologic and Supportive Care Management of Hyperlipidemia

  • Plan individualized, guideline-recommended lipid-lowering treatment strategies using nonstatin or combination therapies to improve patient outcomes
  • Design comprehensive, interprofessional, patient-centered care plans for individuals with or at risk for ASCVD that ensure optimal coordination and access for underserved patients
  • Educate patients and caregivers on the clinical rationale for nonstatin or combination therapies to treat hyperlipidemia, addressing concerns on side effects and providing strategies to promote compliance

First to See, First to Act: Empowering NPs and PAs With Frontline Strategies to Recognize and Treat ATTR-CM

  • Identify the burden, signs, and clinical manifestations of ATTR-CM to facilitate prompt, precise, and thorough diagnosis
  • Formulate individualized treatment strategies using novel disease-modifying therapies to improve patient outcomes
  • Empower patients to understand their ATTR-CM diagnosis and the clinical rationale for disease-modifying therapies, addressing concerns about safety and progression while providing practical strategies to support treatment adherence through shared decision-making

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 6.0 contact hours, including 6.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 6.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies. 

Acknowledgement

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with the Academy of Physician Associates in Cardiology (APAC).

Partners for Advancing Clinical Education (Partners) 2025

Supporter

Leading With Impact: NPs and PAs at the Center of PAH Care Transformation
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

ASCVD Prevention Through Individualized Pharmacologic and Supportive Care Management of Hyperlipidemia
Supported by an educational grant from Novartis Pharmaceuticals Corporation.

First to See, First to Act: Empowering NPs and PAs With Frontline Strategies to Recognize and Treat ATTR-CM
This activity is supported by an educational grant from Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Novartis Pharmaceuticals Corporation

Merck & Co., Inc., Rahway, NJ, USA

Partner

Academy of Physician Associates in Cardiology (APAC)

Academy of Physician Associates in Cardiology (APAC)

Contact Information

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.